Influenza and Other Respiratory Viruses最新文献

{"title":"The Global Influenza Hospital Surveillance Network: A Multicountry Public Health Collaboration","authors":"Marta C. Nunes,&nbsp;Cecile Chauvel,&nbsp;Sonia M. Raboni,&nbsp;F. Xavier López-Labrador,&nbsp;Melissa K. Andrew,&nbsp;Nazish Badar,&nbsp;Vicky Baillie,&nbsp;Antonin Bal,&nbsp;Kedar Baral,&nbsp;Elsa Baumeister,&nbsp;Celina Boutros,&nbsp;Elena Burtseva,&nbsp;Daouda Coulibaly,&nbsp;Ben Cowling,&nbsp;Daria Danilenko,&nbsp;Ghassan Dbaibo,&nbsp;Gregory Destras,&nbsp;Ndongo Dia,&nbsp;Anca Cristina Drăgănescu,&nbsp;Heloisa I. G. Giamberardino,&nbsp;Doris Gomez-Camargo,&nbsp;Laurence Josset,&nbsp;Parvaiz A. Koul,&nbsp;Jan Kyncl,&nbsp;Victor Alberto Laguna-Torres,&nbsp;Odile Launay,&nbsp;Liem Binh Luong Nugyen,&nbsp;Shelly McNeil,&nbsp;Snežana Medić,&nbsp;Ainara Mira-Iglesias,&nbsp;Alla Mironenko,&nbsp;Aneta Nitsch-Osuch,&nbsp;Alejandro Orrico-Sánchez,&nbsp;Nancy A. Otieno,&nbsp;Hadrien Regue,&nbsp;Guillermo M. Ruiz-Palacios,&nbsp;Afif Ben Salah,&nbsp;Muhammad Salman,&nbsp;Oana Săndulescu,&nbsp;Viviana Simon,&nbsp;Anna Sominina,&nbsp;Emilia Sordillo,&nbsp;Mine Durusu Tanriover,&nbsp;Serhat Unal,&nbsp;Harm van Bakel,&nbsp;Philippe Vanhems,&nbsp;Tao Zhang,&nbsp;Catherine Commaille-Chapus,&nbsp;Camille Hunsinger,&nbsp;Joseph Bresee,&nbsp;Bruno Lina,&nbsp;John W. McCauley,&nbsp;Justin R. Ortiz,&nbsp;Cecile Viboud,&nbsp;Wenqing Zhang,&nbsp;Laurence Torcel-Pagnon,&nbsp;Cedric Mahe,&nbsp;Sandra S. Chaves","doi":"10.1111/irv.70091","DOIUrl":"https://doi.org/10.1111/irv.70091","url":null,"abstract":"<p>Respiratory viruses represent a significant public health threat. There is the need for robust and coordinated surveillance to guide global health responses. Established in 2012, the Global Influenza Hospital Surveillance Network (GIHSN) addresses this need by collecting clinical and virological data on persons with acute respiratory illnesses across a network of hospitals worldwide. GIHSN utilizes a standardized patient enrolment and data collection protocol across its study sites. It leverages pre-existing national infrastructures and expert collaborations to facilitate comprehensive data collection. This includes demographic, clinical, epidemiological, and virologic data, and whole genome sequencing (WGS) for a subset of viruses. Sequencing data are shared in the Global Initiative on Sharing All Influenza Data (GISAID). GIHSN uses financing and governance approaches centered around public–private partnerships. Over time, GIHSN has included more than 100 hospitals across 27 countries and enrolled more than 168,000 hospitalized patients, identifying 27,562 cases of influenza and 44,629 of other respiratory viruses. GIHSN has expanded beyond influenza to include other respiratory viruses, particularly since the COVID-19 pandemic. In November 2023, GIHSN strengthened its global impact through a memorandum of understanding with the World Health Organization, aimed at enhancing collaborative efforts and data sharing for improved health responses. GIHSN exemplifies the value of integrating scientific research with public health initiatives through global collaboration and public–private partnerships governance. Future efforts should enhance the scalability of such models and ensure their sustainability through continued public and private support.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70091","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143622613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Phylogenetic Study of Local Patterns Influenza A(H3N2) Virus Transmission in a Semi-Isolated Population in a Remote Island in Japan Between 2011 and 2013","authors":"Su Myat Han,&nbsp;Teiichiro Shiino,&nbsp;Shingo Masuda,&nbsp;Yuki Furuse,&nbsp;Takahiro Yasaka,&nbsp;Satoshi Kanda,&nbsp;Kazuhiri Komori,&nbsp;Nobuo Saito,&nbsp;Yoshiano Kubo,&nbsp;Chris Smith,&nbsp;Akira Endo,&nbsp;Alexis Robert,&nbsp;Marc Baguelin,&nbsp;Koya Ariyoshi","doi":"10.1111/irv.70089","DOIUrl":"https://doi.org/10.1111/irv.70089","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Influenza A outbreak risk is impacted by the potential for importation and local transmission. Reconstructing transmission history with phylogenetic analysis of genetic sequences can help assess outbreak risk but relies on regular collection of genetic sequences. Few influenza genetic sequences are collected in Japan, which makes phylogenetic analysis challenging, especially in rural, remote settings. We generated influenza A genetic sequences from nasopharyngeal swabs (NPS) samples collected using rapid influenza diagnostic tests and used them to analyze the transmission dynamics of influenza in a remote island in Japan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We generated 229 whole genome sequences of influenza A/H3N2 collected during 2011/12 and 2012/13 influenza seasons in Kamigoto Island, Japan, of which 178 sequences passed the quality check. We built time-resolved phylogenetic trees from hemagglutinin sequences to classify the circulating clades by comparing the Kamigoto sequences to global sequences. Spatiotemporal transmission patterns were then analyzed for the largest local clusters.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Using a time-resolved phylogenetic tree, we showed that the sequences clustered in six independent transmission groups (1 in 2011/12, 5 in 2012/13). Sequences were closely related to strains from mainland Japan. All 2011/12 strains were identified as clade 3C.2 (<i>n</i> = 29), while 2012/13 strains fell into two clades: clade 3C.2 (<i>n</i> = 129) and 3C.3a (<i>n</i> = 20). Clusters reported in 2012/13 circulated simultaneously in the same regions. The spatiotemporal analysis of the largest cluster revealed that while the first sequences were reported in the busiest district of Kamigoto, the later sequences were scattered across the island.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Kamigoto Island was exposed to repeated importations of Influenza A(H3N2), mostly from mainland Japan, sometimes leading to local transmission and ultimately outbreaks. As independent groups of sequences overlapped in time and space, cases may be wrongly allocated to the same transmission group in the absence of genomic surveillance, thereby underestimating the risk of importations. Our analysis highlights how NPS could be used to better understand influenza transmission patterns in little-studied settings and improve influenza surveillance in Japan.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70089","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143594922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024","authors":"Liliana Antunes,&nbsp;Madelyn Rojas-Castro,&nbsp;Marcos Lozano,&nbsp;Iván Martínez-Baz,&nbsp;Isabel Leroux-Roels,&nbsp;Maria-Louise Borg,&nbsp;Beatrix Oroszi,&nbsp;Margaret Fitzgerald,&nbsp;Ralf Dürrwald,&nbsp;Ligita Jancoriene,&nbsp;Ausenda Machado,&nbsp;Goranka Petrović,&nbsp;Mihaela Lazar,&nbsp;Lenka Součková,&nbsp;Sabrina Bacci,&nbsp;Jennifer Howard,&nbsp;Nuno Verdasca,&nbsp;Luca Basile,&nbsp;Jesús Castilla,&nbsp;Silke Ternest,&nbsp;Aušra Džiugytė,&nbsp;Gergő Túri,&nbsp;Roisin Duffy,&nbsp;Carolin Hackmann,&nbsp;Monika Kuliese,&nbsp;Verónica Gomez,&nbsp;Zvjezdana Lovrić Makarić,&nbsp;Alexandru Marin,&nbsp;Petr Husa,&nbsp;Nathalie Nicolay,&nbsp;Angela M. C. Rose,&nbsp;VEBIS SARI VE network team","doi":"10.1111/irv.70081","DOIUrl":"https://doi.org/10.1111/irv.70081","url":null,"abstract":"<div>\u0000 \u0000 <p>We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case–control study in Europe. We included older adults (≥ 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14–59 days and 34% at 60–119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.</p>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143581505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurologic Complications of Influenza and Potential Protective Vaccine Effects","authors":"Ann R. Falsey","doi":"10.1111/irv.70071","DOIUrl":"https://doi.org/10.1111/irv.70071","url":null,"abstract":"<p>Influenza is a common respiratory infection affecting persons of all ages and results in significant morbidity and mortality. Respiratory complications are well known, but important nonpulmonary complications are less well recognized. Neurologic complications following influenza infection may accompany the acute illness or may be chronic in nature. The acute complications such as seizures, encephalitis, myelitis and Guillain Barre Syndrome are well documented but fortunately are uncommon. However, stroke and dementia are leading causes of death and disability worldwide, and there is increasing evidence linking these devasting illnesses with influenza. In addition, influenza vaccine has been associated with protective effects against stroke and dementia risk.</p>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70071","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143554586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influenza-Related Deaths in the Czech Republic Over 21 Seasons","authors":"Jan Kyncl,&nbsp;Marek Brabec,&nbsp;Marek Maly,&nbsp;Vojtech Simka,&nbsp;Ales Urban","doi":"10.1111/irv.70072","DOIUrl":"https://doi.org/10.1111/irv.70072","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Influenza is a relatively serious infection that causes considerable morbidity and mortality. Epidemics of influenza are reported almost every year.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Based on the Czech national all-cause mortality and acute respiratory infection/influenza-like illness surveillance data for the 1999/2000 to 2019/2020 influenza seasons, excess deaths attributable to influenza were estimated using the threshold derived as 90th percentile of death counts during nonepidemic periods. Daily death counts broken by the 5-year age intervals were modelled via Poisson generalised additive model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The estimated total number of excess deaths from influenza during study period was 22,306. Thus, the mean total of excess deaths related to influenza per season was 1062 for the age group 40–94 years. The total number of excess deaths increased steadily with age from the 40–44 age group to the 85–89 age group, which accounted for the highest percentage of excess deaths (17%), followed closely by the 80–84 age group (16%). The age groups 40–44 years and 45–49 years contributed the least (3% each). More than three quarters of excess deaths occurred at age 65 and over (17,027 cases; 76%). Relative numbers of excess deaths per 100,000 population peaked in the oldest age groups of 85–89 and 90–94 years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We estimate that at least 0.98% of all-cause mortality throughout the study period was attributable to influenza in the Czech Republic. This excess is not negligible, and public health actions in the field of influenza prevention are vitally needed.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70072","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143554912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Potential for Twice-Annual Influenza Vaccination to Reduce Disease Burden","authors":"Shuyi Zhong,&nbsp;Mark G. Thompson,&nbsp;Benjamin J. Cowling","doi":"10.1111/irv.70052","DOIUrl":"https://doi.org/10.1111/irv.70052","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Influenza vaccination is recommended annually based on the evolving nature of influenza viruses and the waning of vaccine-induced immunity. The timing of vaccination is usually before the winter influenza season in most temperate locations, where the seasonality is clear and influenza activities on average last no longer than 6 months. However, many tropical and subtropical areas have year-round influenza activity and multiple epidemics within 1 year, against which annual influenza vaccination may not offer sufficient protection at the individual level.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>A twice-annual vaccination program could utilize standard inactivated influenza vaccines or enhanced influenza vaccines. Here, we discuss three reasons to consider twice-annual vaccination as a strategy to improve protection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>The first, mentioned above, is that some locations experience prolonged or year-round influenza activity. The second reason is based on the observation that vaccine effectiveness significantly declines about 6 months after vaccination particularly for A(H3N2) strains, and therefore, vaccination twice a year might be beneficial to maintain a higher level of immunity in the second half of each year. The third reason is to allow for receipt of the most updated vaccine strains, given that these are updated twice each year by the World Health Organization. We also discuss three potential barriers or challenges. The first potential challenge is knowledge gaps, because there are very few existing studies that used twice-annual vaccination. The second potential barrier is a concern over whether more frequent vaccination would lead to reduced immunogenicity or reduced clinical protection in the longer term. The third relates to concerns about cost or feasibility.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>We discuss these issues and recommend comparative assessment of the incremental benefits and cost of twice-annual vaccination versus annual vaccination, as well as other vaccination strategies aiming to reduce influenza disease burden particularly in tropical and subtropical locations where there can be year-round influenza activity.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70052","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143554913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severity Scale of Influenza and Acute Respiratory Illness Hospitalizations to Support Viral Genomic Surveillance: A Global Influenza Hospital Surveillance Network Pilot Study","authors":"Bronke Boudewijns,&nbsp;Saverio Caini,&nbsp;Marco Del Riccio,&nbsp;Marta C. Nunes,&nbsp;Sandra S. Chaves,&nbsp;Melissa K. Andrew,&nbsp;Justin R. Ortiz,&nbsp;Oana Săndulescu,&nbsp;Joseph S. Bresee,&nbsp;Elena Burtseva,&nbsp;Daouda Coulibaly,&nbsp;Daria M. Danilenko,&nbsp;Kirill Stolyarov,&nbsp;Anca C. Drăgănescu,&nbsp;Mine Durusu Tanriover,&nbsp;Heloisa I. G. Giamberardino,&nbsp;Parvaiz A. Koul,&nbsp;F. Xavier Lopez-Labrador,&nbsp;Shelly A. McNeil,&nbsp;Ainara Mira-Iglesias,&nbsp;Alejandro Orrico-Sanchez,&nbsp;Nancy A. Otieno,&nbsp;Jorim Ayugi,&nbsp;Sonia M. Raboni,&nbsp;Peter Spreeuwenberg","doi":"10.1111/irv.70085","DOIUrl":"https://doi.org/10.1111/irv.70085","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This study aimed to establish a Severity Scale for influenza and other acute respiratory infections (ARI), requiring hospitalization, for surveillance and research purposes (the SevScale). Such a scale could aid the interpretation of data gathered from disparate settings. This could facilitate pooled analyses linking viral genetic sequencing data to clinical severity, bringing insights to inform influenza surveillance and the vaccine strain selection process.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We used a subset of data from the Global Influenza Hospital Surveillance Network database, including data from different geographical areas and income levels. To quantify the underlying concept of severity, an item response model was developed using 16 indicators of severity related to the hospital stay. Each patient in the dataset was assigned a Severity Score and a Severity Category (low, medium, or high severity). Finally, we compared the model scores across different subgroups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Data from 9 countries were included, covering between 4 and 11 seasons from 2012 to 2022, with a total of 96,190 ARI hospitalizations. Not for all severity indicators data were available for all included seasons. Subgroups with a high percentage of patients in the high Severity Category included influenza A(H1N1)pdm09, age ≥ 50, lower-middle income countries, and admission since the start of the COVID-19 pandemic.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The initial model successfully highlighted severity disparities across patient subgroups. Repeating this exercise with new, more complete data would allow recalibration and validation of the current model. The SevScale proved to be a promising method to define severity for influenza vaccine strain selection, surveillance, and research.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70085","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143554887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adult Vaccine Coadministration Is Safe, Effective, and Acceptable: Results of a Survey of the Literature","authors":"Litjen Tan,&nbsp;L.J,&nbsp;Dana Trevas,&nbsp;Ann R. Falsey","doi":"10.1111/irv.70090","DOIUrl":"https://doi.org/10.1111/irv.70090","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Coadministration of vaccines in children is a long-standing practice that has proven to be safe and effective in improving the efficiency of vaccine administration, thereby increasing immunization coverage rates. As the number of vaccines routinely recommended for adults increases, and with limited opportunities for adults to have preventive health touchpoints with providers, adult vaccine coadministration should be considered as a routine practice to improve vaccination coverage rates and public health. A review of existing literature was conducted to examine the potential reactogenicity and impact on effectiveness when co-administering vaccines to adults.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Medline was searched for research articles with the search term “influenza vaccine” or “vaccination,” combined with the search terms “simultaneous,” “concomitant,” “concurrent,” and “combination.” Another search of Medline was conducted on the search term “influenza vaccine” or “vaccination” combined with the following individual search terms: “RSV,” “COVID,” and “Tdap.” The references of extracted articles were also examined for potential other relevant articles.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results and Conclusions</h3>\u0000 \u0000 <p>Adult vaccine coadministration is safe for all the combinations we assessed. Most adverse events (AEs) were generally mild to moderate and of short duration. Some studies showed slightly more reactogenicity with coadministration but few or no serious AEs or safety signals. Nearly every study confirmed that coadministration had no significant effect on immune response for either vaccine. The benefits of vaccine coadministration outweigh the risks. It increases convenience for vaccinees, reduces the number of missed opportunities to vaccinate, and contributes to efficient use of healthcare resources.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70090","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143554301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shifts in Respiratory Virus Epidemiology on Reunion Island From 2017 to 2023: Impact of COVID-19 Pandemic and Non-Pharmaceutical Interventions","authors":"Nicolas M'nemosyme,&nbsp;Etienne Frumence,&nbsp;Laurent Souply,&nbsp;Diana Heaugwane,&nbsp;Nicolas Traversier,&nbsp;Alizé Mercier,&nbsp;Jamel Daoudi,&nbsp;Jean-Sébastien Casalegno,&nbsp;Martine Valette,&nbsp;Marie-Pierre Moiton,&nbsp;Rodolphe Manaquin,&nbsp;Etienne Darieux,&nbsp;Raphaëlle Sarton,&nbsp;Anaïs Grimal,&nbsp;Fabian Thouillot,&nbsp;Xavier Deparis,&nbsp;Bruno Lina,&nbsp;Marie-Christine Jaffar-Bandjee","doi":"10.1111/irv.70075","DOIUrl":"https://doi.org/10.1111/irv.70075","url":null,"abstract":"&lt;p&gt;The emergence of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), in late December 2019 in Wuhan, China, has had a profound impact worldwide [&lt;span&gt;1, 2&lt;/span&gt;]. Reunion Island, situated in the southwest of the Indian Ocean and spanning 2500 km&lt;sup&gt;2&lt;/sup&gt; as a French overseas department, is inhabited by around 885,700 people, primarily residing along the coastal areas. On this island, the first case of COVID-19 was reported on March 11, 2020, at the University Hospital Center (UHC) of La Reunion, in a group of travelers returning from a cruise [&lt;span&gt;3&lt;/span&gt;]. Given the lack of available treatments to combat the infection during that period, the government implemented a comprehensive array of public health measures on Reunion Island, similar to those in metropolitan France, in an effort to control the spread of the virus. These measures, referred to as non-pharmaceutical interventions (NPIs), included a strict lockdown period and the closure of all schools and childcare centers on the island from March 17, 2020, to May 11, 2020. Subsequently, in August 2020, control measures were formally introduced on the island, encompassing social distancing and mandatory mask-wearing in public. Starting in July 2020, several SARS-CoV-2 screening campaigns were launched across all cities on the island, aiming to test all travelers entering and leaving the island, as well as all hospital admissions.&lt;/p&gt;&lt;p&gt;These NPIs were implemented both to reduce the transmission of the virus and to prevent the healthcare system from exceeding its capacity of intensive care beds [&lt;span&gt;4&lt;/span&gt;]. Thanks to these measures, Reunion Island registered only 9037 cases and 42 deaths during the initial year of the COVID-19 pandemic, managing to remain relatively unscathed [&lt;span&gt;5&lt;/span&gt;]. The vaccination campaign began on January 15, 2021, and in the subsequent months, a range of new NPIs, including lockdowns and curfews, were introduced. Nevertheless, the island encountered numerous successive waves of infection caused by different variants of SARS-CoV-2 (such as Beta, Delta, and Omicron variants) [&lt;span&gt;6&lt;/span&gt;]. This led to over 82,796 reported cases in 2021 and a surge to more than 420,850 cases in 2022, according to regional public health authority statistics [&lt;span&gt;6, 7&lt;/span&gt;]. The year 2023, on the other hand, was a year of low SARS-CoV-2 circulation on the island [&lt;span&gt;8&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;It has been reported that the combination of SARS-CoV-2 circulation and NPIs across the world has had a significant impact on the circulation of other respiratory viruses [&lt;span&gt;9-14&lt;/span&gt;]. Notably, a global decline in influenza cases and a shift in the seasonal transmission pattern of respiratory syncytial virus (RSV) were evident worldwide. In mainland France, no influenza outbreaks were reported for the 2020–2021 season following the implementation of NPIs, while the RSV bronchiolitis outbreak in children was delayed ","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70075","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143554300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Excess All-Cause Mortality by Age and Gender During the COVID-19 Pandemic in the Federation of Bosnia and Herzegovina, Bosnia and Herzegovina: 2020–2022","authors":"Šeila Cilović-Lagarija,&nbsp;Johanna Thea Mølgaard Rantzau,&nbsp;Siniša Skočibušić,&nbsp;Sanjin Musa,&nbsp;Armin Sprečo,&nbsp;Amna Isaković,&nbsp;Mirza Palo,&nbsp;Faris Dizdar,&nbsp;Hidajeta Čolović,&nbsp;Veronica Ivey Sawin,&nbsp;Jens Nielsen,&nbsp;Pernille Jorgensen","doi":"10.1111/irv.70086","DOIUrl":"https://doi.org/10.1111/irv.70086","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>COVID-19 has had a profound impact on global mortality and morbidity, yet only a fraction of deaths was confirmed and reported. We estimated all-cause excess mortality from 1 January 2020 to 31 December 2022 in the Federation of Bosnia and Herzegovina (FBiH) to assess the true magnitude of the pandemic.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data for this analysis was sourced from the FBiH mortality register and supplemented with population statistics and official COVID-19 death counts (i.e., cases where COVID-19 was registered as the cause of death). Using a Poisson model, all-cause excess number of deaths and rates per 100,000 person-years, adjusted for registration delays and stratified by age and gender, were calculated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>FBiH experienced three periods of excess all-cause mortality throughout the first 3 years of the pandemic, with a total of 12,000 excess deaths, highest among adults 45–74 years and males. No excess mortality was observed in children &lt;15 years.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The true mortality impact of COVID-19 in FBiH was substantially higher than the reported deaths, including among younger adults. Strengthening civil registration and vital statistics, including establishment of all-cause mortality surveillance, is essential for improved monitoring of future pandemics and other important public health events. A detailed review of the direct and indirect effects of COVID-19 on mortality should be conducted to identify areas that require more resources, improve health provision and inform mitigation efforts in future pandemics to save lives.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 3","pages":""},"PeriodicalIF":4.3,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70086","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143497105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}